Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)

被引：0
|
作者：
Liu, Xiufeng [1 ]
Lu, Yinying [2 ]
Zhou, Weiping [3 ]
Peng, Tao [4 ]
Zhou, Jie [5 ]
Bi, Huaqiang [6 ]
Xia, Feng [6 ]
Chen, Xiaoping [7 ]
机构：
[1] Jinling Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Peoples R China
[2] Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China
[3] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China
[4] Guangxi Med Univ, Affiliated Hosp 1, Hepatobiliary Surg Dept, Nanning, Peoples R China
[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Hepatobiliopancreat Surg & Liver Transplantat, Guangzhou, Peoples R China
[6] Army Med Univ, Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China
[7] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China
来源：
LIVER CANCER | 2024年 / 13卷 / 04期
关键词：
Hepatocellular carcinoma; Immunotherapy; Combination therapy; Immune checkpoint inhibitors; Multidisciplinary team; Consensus; TENOFOVIR DISOPROXIL FUMARATE; OPEN-LABEL; DOUBLE-BLIND; CONVERSION THERAPY; SINTILIMAB PLUS; SORAFENIB; PHASE-3; IMMUNOTHERAPY; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.1159/000535496
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.
引用
收藏
页码：355 / 375
页数：21
相关论文
共 50 条
  • [21] Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status
    Carril-Ajuria, Lucia
    Colomba, Emeline
    Romero-Ferreiro, Carmen
    Cerbone, Luigi
    Ratta, Raffaele
    Barthelemy, Philippe
    Vindry, Clarisse
    Flechon, Aude
    Cherifi, Francois
    Boughalem, Elouen
    Linassier, Claude
    Fornarini, Giuseppe
    Rebuzzi, Sara E.
    Gross-Goupil, Marine
    Saldana, Carolina
    Martin-Soberon, Maricruz
    de Velasco, Guillermo
    Manneh, Ray
    Pernaut, Cristina
    de Torre, Ana Sanchez
    Flippot, Ronan
    Escudier, Bernard
    Albiges, Laurence
    EUROPEAN JOURNAL OF CANCER, 2023, 180 : 21 - 29
  • [22] The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study
    Yang, Chao-Xu
    Pan, Yang-Xun
    Ye, Feng
    Zhu, Xiao-Dong
    Xue, Jun
    Li, Xi
    Yuan, Zhen-Gang
    Zhang, Lan
    Xu, Li
    Chen, Yong-Jun
    Wang, Nan-Ya
    Sun, Hui-Chuan
    Liu, Xiu-Feng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [23] Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy
    He, Mengying
    Yang, Tao
    Wang, Yuhan
    Wang, Mengyuan
    Chen, Xingye
    Ding, Dawei
    Zheng, Yiran
    Chen, Huabing
    ADVANCED HEALTHCARE MATERIALS, 2021, 10 (09)
  • [24] Chinese Expert Consensus on the Combination of Targeted Therapy and Immunotherapy with Locoregional Therapy for Intermediate/Advanced Hepatocellular Carcinoma
    Bi, Xinyu
    Lu, Yinying
    Chen, Bo
    Yang, Zhengqiang
    Hong, Zhixian
    Wang, Hanping
    Sun, Yongkun
    Wang, Xiaodong
    Yuan, Chunwang
    Zeng, Daobing
    Huang, Zhen
    Zhou, Aiping
    Zhang, Wen
    Du, Shunda
    Zhao, Jianjun
    Zhou, Jianguo
    Zhai, Yirui
    Che, Xu
    Zhao, Hong
    Zhao, Haitao
    Cai, Jianqiang
    LIVER CANCER, 2024,
  • [25] Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma
    Kim, Ha Il
    Lim, Jihye
    Shim, Ju Hyun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2069 - 2077
  • [26] Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma
    Ha Il Kim
    Jihye Lim
    Ju Hyun Shim
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2069 - 2077
  • [27] Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
    Daniel Roessler
    Osman Öcal
    Alexander B. Philipp
    Daniel Markwardt
    Stefan Munker
    Julia Mayerle
    Leonie S. Jochheim
    Katharina Hammer
    Christian M. Lange
    Andreas Geier
    Max Seidensticker
    Florian P. Reiter
    Enrico N. De Toni
    Najib Ben Khaled
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 3065 - 3073
  • [28] Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study
    Roessler, Daniel
    Oecal, Osman
    Philipp, Alexander B.
    Markwardt, Daniel
    Munker, Stefan
    Mayerle, Julia
    Jochheim, Leonie S.
    Hammer, Katharina
    Lange, Christian M.
    Geier, Andreas
    Seidensticker, Max
    Reiter, Florian P.
    De Toni, Enrico N.
    Ben Khaled, Najib
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3065 - 3073
  • [29] Impact of immune checkpoint inhibitor-based combination therapy on palliative care utilization for patients with metastatic renal cell carcinoma.
    Baclig, Nikita V.
    Cabral, Marsenne Y.
    Kathuria-Prakash, Nikhita
    Velez, Maria Antonia
    Pantuck, Allan J.
    Drakaki, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma
    Tamai, Yasuyuki
    Fujiwara, Naoto
    Tanaka, Takamitsu
    Mizuno, Shugo
    Nakagawa, Hayato
    CANCERS, 2023, 15 (20)
12345